Acrp30 inhibited angiogenesis using in vitro and in vivo assays of non-breast cancer cell lines and the intratumoral injection of Acrp30 suppressed T241 fibrosarcoma tumour growth (Brakenhielm et al, 2004). Here, ADIPOQ is linked to breast carcinoma.